Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 136572-09-3 | Product Number: I0714
Irinotecan Hydrochloride Trihydrate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- CPT-11 Trihydrate
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 100MG |
$84.00
|
3 | 1 | ≥80 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | I0714 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__3__3H__3__8N__4O__6·HCl·3H__2O = 677.20 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 136572-09-3 |
| Related CAS RN | 100286-90-6&97682-44-5 |
| Reaxys Registry Number | 4838283 |
| PubChem Substance ID | 87560270 |
| Merck Index (14) | 5091 |
| MDL Number | MFCD01765731 |
Specifications
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Specific rotation [a]20/D | +22.0 to +26.0 deg(C=1, methanol) |
| Water | 7.0 to 10.0 % |
Properties (reference)
| Boiling Point | 257 °C |
| Specific Rotation | 24° (C=1,MeOH) |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H372 : Causes damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P314 : Get medical advice/ attention if you feel unwell. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | DW1060750 |
Transport Information:
| HS Number | 2942.00.0500 |
Application
Irinotecan hydrochloride (CPT-11): A Water Soluble Topoisomerase-I Inhibitor with Enhanced Activity
Irinotecan hydrochloride (CPT-11) is a derivative of 7-ethylcamptothecin (SN-22) [E0781] or Camptothecin (CPT) [C1495]. Irinotecan hydrochloride has greater water solubility and enhanced topoisomerase-I inhibitory activity than theirs. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) [E0748] by a carboxylesterase-converting enzyme. Camptotecin and its derivatives interfere with DNA synthesis by inhibiting the enzyme topoisomerase-I. In order to prevent and correct of topological problems caused by the DNA double helix, topoisomerase-I catalyzes the relaxation of negatively supercoiled DNA, the knotting and unknotting DNA and the linking complementary rings of single-stranded DNA into double-stranded rings. Then the inhibition action induces breaks in single strand DNA. Eventually, this leads to double-strand DNA breaks and apoptosis or cell death. (The product is for research purpose only.)
References
- Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin
- Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38
- Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) (a review)
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
- The camptothecins (a review)
- Pharmacogenetics of irinotecan metabolism and transport: An update
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.